Vertical Patent-Cliff Exposure & CMS Drug Spending Portfolio
Vertical (US): 3 reconciled FDA prescription therapies, $858K 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 3 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $858K |
| 2024 Medicare Part D Spend | $629K |
| 2024 Medicaid Spend | $230K |
| California HCAI SB 17 Filings | 8 WAC filings (max 34.5% 2-yr change) |